Tetrahydrobenzo Naphthyridine Kinase Inhibitors for Multi-Pathway Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for disorders related to unregulated tyrosine kinase signal transduction, such as cancer and blood vessel proliferative disorders, often target single pathways, which may not provide sufficient therapeutic effect, and there is a need for compounds that can modulate both VEGF and PDGF receptors to address these conditions effectively.
Innovation Solution
Development of organic molecules represented by Formula I, which can inhibit or modulate tyrosine kinase signal transduction by blocking VEGF and/or PDGF receptors, offering a broader therapeutic impact on various diseases including cancer, diabetic retinopathy, and age-related macular degeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single pathway targeting is used in current treatments, then treatment simplicity is maintained, but therapeutic effectiveness is insufficient
Solution Approach 1:
The patent applies multi-functionality by designing a single compound (Formula I) that can simultaneously inhibit multiple tyrosine kinase pathways including VEGF and PDGF receptors. This allows one drug molecule to perform multiple therapeutic functions, addressing the contradiction by improving effectiveness through pathway coverage without requiring multiple separate treatments
2Reliability
If multiple pathways are targeted to improve therapeutic effect, then comprehensive disease treatment is achieved, but compound design complexity increases
Solution Approach 1:
The patent merges multiple pathway inhibition capabilities into a single compound structure (Formula I). By combining structural elements that enable binding to different tyrosine kinase receptors (VEGF, PDGF) within one molecule, the invention achieves comprehensive pathway targeting without requiring separate compounds for each pathway
Solution Approach 2:
The compound of Formula I functions as a composite molecular structure incorporating multiple pharmacophoric elements that enable interaction with different kinase targets. This composite design allows simultaneous engagement of multiple pathways while maintaining a unified molecular entity
3Adaptability or versatility
If broader pathway inhibition is implemented, then disease coverage is expanded, but selectivity among kinases may be compromised
Solution Approach 1:
The patent applies local quality by incorporating specific structural features within Formula I that provide selective binding characteristics for different kinase subtypes. Certain substituents and molecular regions are designed to interact preferentially with specific amino acid residues in the kinase binding pocket, enabling differentiated binding affinity across the tyrosine kinase family
Data Source
AI summary
The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.